In a study conducted at UPMC, researchers assessed Ibex Prostate’s performance in primary diagnosis of prostate biopsies, employed in a digital pathology workflow. The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting. The study also demonstrated positive feedback from participating pathologists, showing high satisfaction, particularly with Ibex Prostate’s Gleason scoring, detection of perineural invasion and automated measurement of tissue and tumor length.
The current Ibex offering was formerly known as Galen. Please note that any mention of Galen within these materials refers to a product now known as Ibex.
